FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 04/2025”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of April 2025 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 12,809m (-9% vs. 2024)
- While US VC financing volume in Healthcare & Life Sciences is declining vs. last year’s volume, Europe’s financing volume is 32% higher than last year
- Biotech/Pharma received 43% of the total investment volume (EUR 5,567m) with oncology being the leading indication (25%)
- In April Transcarent secured the highest transaction volume with EUR 437m, followed by Cognito Therapeutics with EUR 181m and Atsena Therapeutics with EUR 138m
- Illumina (United States) is the most active investor (by deal volume in 2025), followed by Regeneron Pharmaceuticals (United States) and Bain Capital Life Sciences (United States)
To access the full report, please click here.